Oral Immunotherapy for Egg Allergy in Children Aged 6 to 16

Egg Allergy Clinical Trial

Official title:

Oral Immunotherapy for Egg Allergy in Children Aged 6 to 16

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05740163
• Other study ID #: Oral immunotherapy fo egg
• Status: Recruiting
• Phase: N/A
• Start date: December 30, 2019
• Est. completion date: December 31, 2026

Study information

• Verified date: April 2024
• Source: Tampere University Hospital
• Contact: Rüdiger Schultz, MD., PhD
• Phone: +358
• Email: rudiger.schultz58[@]gmail.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The aim of the study is to determine the efficacy of a 12-month egg oral immunotherapy (OIT) protocol with a cooked whole egg product including yolk and egg white.

Study hypothesis: With this method the risk for severe allergic reaction to egg protein is reduced and the diet can partly or completely be normalized.

Description:

The prevalence of egg allergy among children varies from 0.5% to 3% and is thus the second most common food allergy in children. Until recently, the only treatment for egg allergy was in many cases a life-long avoidance of egg protein. Due to the large number of egg-allergic children, oral immunotherapy (OIT) to egg has been suggested to be of probable benefit to cure children with egg-allergy. Several studies have been conducted to evaluate the safety and clinical outcome of egg OIT. However, concerning efficacy and safety of egg OIT more data, and alternative procedures are required to gain a safe, simple and inexpensive immunotherapy protocol . Previous egg OIT studies have mainly used egg white in the immunotherapy, rather than more natural and inexpensive whole egg products.

The aim of this study is to determine the efficacy of a 12-month egg oral immunotherapy (OIT) protocol with a cooked whole egg product including yolk and egg white. Furthermore, the effects of whole egg OIT on humoral immune responses are investigated.

The investigators hypothesize that oral administration of a whole egg product with incremental dosing will increase the individual threshold for allergic reactivity to egg protein and may result in full tolerance without any reaction to egg.

Other study aims include investigating the differences in efficacy and side effects of whole-egg OIT in children with asthma and without asthma. In this study it is hypothesized that children with asthma have more symptoms than non-asthmatic children during the treatment. Furthemore, the level of asthma control during OIT is investigated.

The study is a prospective multicenter randomized open trial, investigating the efficacy, safety and immunological mechanisms of oral egg immunotherapy in children (aged 6 to 16). Children with egg allergy, egg avoidance diet, immediate reaction in a food challenge test for egg within the last six months and elevated serum egg-specific immunoglobulin E (IgE) levels, are recruited into the study. Children with uncontrolled asthma, severe cardiovascular disease and autoimmune disease or families with poor compliance are excluded from the study.

Study participants are divided into two groups: patients with asthma and without asthma. Both groups are separately randomized into immunotherapy or follow-up without the treatment. The immunotherapy and follow-up last 12 months in total. After 12 months of enrolment, participants in the follow-up group are entitled to take actively part in the egg OIT protocol.

In immunotherapy groups (asthma or no-asthma), meatball, bun or bread roll, including well-cooked whole-egg is given daily to the patients, starting from a minimal dosage (1/200 of the protein content of whole egg) and increasing the dosing every 1-2 weeks until a dosage of 1/5 of the protein content of a whole egg is reached. The initial dosage is given at the hospital outpatient clinic. The patients and their parents will be prepared for emergency treatment of severe allergic reactions and are given instructions to carry adequate medication with them. Patients in the intervention groups take levocetrizine 5 mg or cetirizine 10 mg daily until three months of maintenance dosage.

Blood samples, skin prick tests, lung function tests and exhaled nitric oxide levels are taken from all study participants. All the above-mentioned tests are taken before the therapy and at the time points of 6 and 12 months.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 60
• Est. completion date: December 31, 2026
• Est. primary completion date: December 31, 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 6 Years to 16 Years

Eligibility

Inclusion Criteria:

• Age 6 to 16 years

• Elevated spesific serum IgE to egg (> 5 kU/l) and/or positive skin prick to egg allergen

• Positive oral food challenge for egg or anaphylaxis reaction to egg within the 6 months

• Diet free from egg in any form

Exclusion Criteria:

• Age less than 6 years or more than 16 years

• Poor asthma control or uncontrolled asthma

• Severe/significant cardiovascular disease

• Autoimmune disease

• Malignancy

• Medication: beta bloker, angiotensin-converting-enzyme inhibitors (ACE inhibitors), Monoamine oxidase inhibitors (MAOIs)

• Poor compliance

• Fear of immunotherapy

• Desensitization to alfa-gal-protein (mammalian meat allergy)

Related Conditions & MeSH terms

• Egg Allergy
• Egg Hypersensitivity
• Hypersensitivity

Intervention

Dietary Supplement:
• Egg product including egg white and yolk allergens
Egg product either meatball or bread roll or bun including egg white and yolk allergens delivered orally in increasing dosages daily.

Locations

Country	Name	City	State
Finland	Oulu University Hospital	Oulu
Finland	Tampere University Hospital	Tampere

Sponsors (3)

Lead Sponsor	Collaborator
Tampere University Hospital	Oulu University Hospital, University of Oulu

Country where clinical trial is conducted

Finland, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Efficacy of oral egg immunotherapy	Total number of patients who achieved tolerance to egg protein during OIT (negative egg challenge) compared to the number of patients who received only partly tolerance or failed to develop any level of unresponsiveness.	Within 12 months of study
Secondary	Safety of oral egg immunotherapy	Total number of participants with adverse events, and total number of adverse events evaluating the safety of our method	Within 12 months of study
Secondary	Specification of adverse reactions during egg OIT in patients without asthma	Subjective evaluation and grading of symptoms from different organ sides during OIT, using visual analogue score 0-10 (VAS) in patients without asthma	Within 12 months of study
Secondary	Number and severity of anaphylactic reactions during OIT without asthma	Number and severity of anaphylaxis during OIT (Grading of anaphylaxis using Samsons criteria, grade1-5) in patients without asthma	Within 12 months of study
Secondary	Specification of adverse reactions during OIT in patients with asthma	Subjective evaluation and grading of symptoms from different organ sides during OIT, using visual analogue score 0-10 (VAS) in patients with asthma	Within 12 months of study
Secondary	Number and severity of anaphylactic reactions durin OIT in patients with asthma	Number and severity of anaphylaxis in patients with asthma (Grading of anaphylaxis using Samsons criteria, grade 1-5) in patients with asthma.	Within 12 months of study
Secondary	Effect of immunotherapy on the level of whole serum IgE	Changing values in blood samples during OIT describing changes in whole IgE by determining values before OIT and after 6 and 12 months of OIT.	Within 12 months of study
Secondary	Effect of immunotherapy on the level of specific egg IgE (sIgE)	Changing values in blood samples during OIT describing changes in egg sIGE by determining values before OIT and after 6 and 12 months of OIT.	Within 12 months of study
Secondary	Effect of immunotherapy on white blood cells	Changing values in blood samples during OIT describing changes in the white blood-cell count by determining values before OIT and after 6 and 12 months of OIT.	Within 12 months of study
Secondary	Effect of immunotherapy on the level of egg IgG4 (sIgG4)	Changing values in blood samples during OIT describing changes in the egg sIgG4 by determining values before OIT and after 6 and 12 months of OIT.	Within 12 months of study
Secondary	Effect of immunotherpay on heat stable, egg components	Changing values in blood samples during OIT describing changes in the heat stable molecules of Gal d1 and Gal d2 by determining values before OIT and after 6 and 12 months of OIT.	Within 12 months of study
Secondary	Effect of immunotherpay on the activity of eosinophils	Changing values in blood samples during OIT describing changes in the level of eosinophilic cationic protein (ECP) by determining values before OIT and after 6 and 12 months of OIT.	Within 12 months of study
Secondary	Changes in parameters describing lung inflammation in patients with asthma	Comparison of values of exhaled nitric oxide (ppb) and serum ECP (ug/l) by comparing the results 6 and 12 months after starting OIT to baseline values before OIT.	Within 12 months of study
Secondary	Changes in parameters describing lung inflammation in patients without asthma	Comparison of values of exhaled nitric oxide (ppb) and serum ECP (ug/l) by comparing the results 6 and 12 months after starting OIT to baseline values before OIT.	Within 12 months of study
Secondary	Changes in lung function parameters during OIT in patients with asthma and > 7 years of age	Effect of OIT on parameters describing lung function in children over > 7 years of age employing flow-volume spirometry. Changing levels of FEV1 (l) and PEF (l/s) will be recorded.	Within 12 months of study
Secondary	Changes in lung function parameters during OIT in patients with asthma < 7 years of age	Effect of OIT on parameters describing lung function in children < 7 years of age employing impedance oscillometry. Changing levels of 5Hz resistance (R5, kPa/l/s) and total impedance (Z5, kPa/l/s) will be recorded.	Within 12 months of study
Secondary	Changes in lung function parameters during OIT in patients without asthma and > 7 years of age	Effect of OIT on parameters describing lung function in children over > 7 years of age and without ashma employing flow-volume spirometry. Changing levels of FEV1 (l) and PEF (l/s) will be recorded.	Within 12 months of study
Secondary	Changes in lung function parameters during OIT in patients without asthma and < 7 years of age	Effect of OIT on parameters describing lung function in children < 7 years of age and without asthma employing impedance oscillometry. Changing levels of 5Hz resistance (R5, kPa/l/s) and total impedance (Z5, kPa/l/s) will be recorded.	Within 12 months of study
Secondary	Recording of asthma symptoms during egg OIT in patients with asthma	Subjective evaluation and grading of asthmatic symptoms during OIT, using visual analogue score (VAS).	Within 12 months of study
Secondary	Recording of asthma symptoms during egg OIT in patients without asthma	Subjective evaluation and grading of asthmatic symptoms during OIT, using visual analogue score (VAS).	Within 12 months of study